EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

From Joint Clinical Assessment to National Decisions: EU HTA Implementation and Implications for Patient Access

Kalpana D'Oca, Ada Adriano iD, Eline Darquennes, Natalie Steck

Journal of Market Access & Health Policy · 19.08.2026 · 14 (3) · 50

DOI: 10.3390/jmahp14030050 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Market Access & Health Policy, online erschienen am 19.08.2026. Verfasst von Kalpana D'Oca und 3 weiteren Autor:innen. Beteiligte Einrichtung: MSD (UK) Limited, London EC2M 6UR, UK. Die Arbeit nennt 22 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: MSD International & Development GmbH, Switzerland.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The introduction of Joint Clinical Assessments (JCAs) under the European Union Health Technology Assessment Regulation (EU HTAR) represents a major structural reform aimed at reducing fragmentation and duplication in clinical evidence assessment across Member States. While JCAs are intended to support national health technology assessment (HTA) processes through a common EU-level clinical evaluation, their integration into established national HTA and reimbursement systems remains untested at this early stage of implementation. This paper reports findings from two surveys conducted in 2025 among local affiliate representatives with expertise in relevant HTA and market access activities across 25 European countries (comprising 24 EU Member States and Norway), capturing early national perspectives on key aspects of JCA implementation. The surveys explored anticipated impact on national reimbursement timelines, current opportunities for early HTA advice and PICO input, approaches to handling post-JCA data availability, and nationally prioritised policy and implementation issues. Results indicate mixed expectations regarding the potential impact of JCA on reimbursement timelines, with perceived risks of delay largely viewed as possibly transitional and mitigable through national process adaptation. Respondents emphasised the importance of transparency in PICO consolidation and clarity on the use of JCA reports in national appraisals. Overall, the findings suggest that JCA may represent a reconfiguration rather than a centralisation of evidence assessment, with national influence exercised earlier in the assessment lifecycle. These insights provide policy-relevant input to inform ongoing EU HTA implementation and future refinement of the JCA framework.

Schlagwörter

Stichwörter der Autor:innen

EU HTAJCAPICO scopingnational reimbursement timelines

Autor:innen und Institutionen

  • MSD (UK) Limited, London EC2M 6UR, UK.
  • MSD Belgium, 1170 Brussels, Belgium.
  • MSD Innovation & Development GmbH, CH-8058 Zurich, Switzerland.

ORCID-Profile: Ada Adriano

Förderung

  • MSD International & Development GmbH, Switzerland

Zitieren

APA

D'Oca, K., Adriano, A., Darquennes, E., & Steck, N. (2026). From Joint Clinical Assessment to National Decisions: EU HTA Implementation and Implications for Patient Access. Journal of Market Access & Health Policy, 14(3), 50. https://doi.org/10.3390/jmahp14030050

Vancouver

D'Oca K, Adriano A, Darquennes E, Steck N. From Joint Clinical Assessment to National Decisions: EU HTA Implementation and Implications for Patient Access. Journal of Market Access & Health Policy. 2026;14(3):50. doi:10.3390/jmahp14030050

BibTeX
@article{DOca2026,
  author = {D'Oca, Kalpana and Adriano, Ada and Darquennes, Eline and Steck, Natalie},
  title = {From Joint Clinical Assessment to National Decisions: EU HTA Implementation and Implications for Patient Access},
  journal = {Journal of Market Access & Health Policy},
  year = {2026},
  volume = {14},
  number = {3},
  pages = {50},
  doi = {10.3390/jmahp14030050}
}
Kostenlos starten →